DIP Episode 55 - Cardiac Pharmacology for the USMLE Step 1 (Part 1)

Source / episode info

• Episode: 55
• Title: Divine Intervention Episode 55 – Cardiac Pharmacology for the USMLE Step 1 (Part 1)
• Published: 2018-10-04
• Source: Episode page

One-liner

This episode details the five phases of the myocardial action potential and three phases of the pacemaker potential, focusing on Class I antiarrhythmics (sodium and potassium channel blockers) and emphasizing critical management principles for Wolff-Parkinson-White syndrome (WPW).

High-yield summary

• Myocardial AP: Phase 0 (Fast Na+ influx/Depolarization); Phase 2 (Ca++ influx + Na+ influx); Phase 3 (Delayed rectifier K+ efflux/Repolarization).
• Pacemaker Potential: Automaticity is driven by the "funny current" (I_f) in Phase 4. Sympathetic stimulation increases I_f slope; Parasympathetic decreases it.
• Class I Antiarrhythmics: These drugs block Na+ channels and are classified based on their specific effect: Class IA (Na+ & K+ blocker, prolongs QT); Class IB (Phase 2 Na+ blocker, shortens APD); Class IC (Pure Na+ blocker, no change in APD).
• EKG Correlation: QRS complex reflects ventricular depolarization (fast); QT interval reflects ventricular repolarization (slow). Prolonging the action potential duration primarily prolongs the QT interval.
• WPW Syndrome Management: Never use AV nodal blockers (e.g., Beta-blockers, non-dihydropyridine CC Bs) in suspected WPW because they increase conduction through the accessory pathway (Bundle of Kent), risking rapid ventricular rates and sudden death.

Learning objectives

• Describe the electrophysiology of the myocardial action potential and pacemaker potential phases.
• Differentiate the mechanisms of Class I antiarrhythmics (IA, IB, IC) based on their specific ion channel blockade.
• Predict the resulting changes in QRS width versus QT interval duration following drug administration.
• Identify contraindications for rate control agents in patients with Wolff-Parkinson-White syndrome (WPW).
• Recognize and manage the clinical manifestations of Digoxin toxicity.

Board exam buzzwords

Rapid review table

Board-speak -> diagnosis

Differential diagnosis / distinguishing features

Rate Control Agents in WPW Syndrome

Management pearls

• In suspected WPW syndrome, the primary goal of rate control is achieved by administering agents that do not block AV nodal conduction (e.g., amiodarone or specific calcium channel blockers if necessary).
• When managing Digoxin toxicity, supportive care and Digoxin-specific antibody fragments (Fab) are used to bind free drug circulating in the plasma.
• The classic triad of Digoxin toxicity is gastrointestinal symptoms (nausea/vomiting), bradycardia, and visual disturbances (yellow/green halos).
• For rate control in severe heart failure where contractility preservation is paramount, IVABRA-DIN is preferred over Beta-blockers because it lacks negative inotropic effects.

Don't miss

Integration & clinical reasoning

• Pharmacology/Electrophysiology: The understanding of ion channel kinetics (Na+, K+, Ca++) is fundamental to predicting drug effects on cardiac rhythm and conduction.
• Cardiology/Internal Medicine: Recognizing the difference between rate control mechanisms (slowing SA/AV nodes) and rhythm control mechanisms (restoring normal sinus rhythm) is crucial for patient management.
• Toxicology: Digoxin toxicity highlights how inhibition of a fundamental pump (\text{Na}^+/\text{K}^+-AT Pase) can cascade into severe, life-threatening cardiac arrhythmias via secondary \text{Ca}^{2+} dysregulation.

OMM / COMLEX integration

• Acute Cardiac Crisis: In any unstable patient with suspected life-threatening arrhythmia (e.g., VT), standard emergency management (ACLS protocols) takes absolute priority over OMT. Antiarrhythmics must be administered rapidly according to established guidelines.
• Drug Toxicity: The mechanism of Digoxin toxicity (\text{Na}^+/\text{K}^+-AT Pase inhibition -> secondary \text{Ca}^{2+} dysregulation) is a key example of how metabolic/pump failure can lead to severe electrical instability, emphasizing the importance of understanding ion gradients.

Concept connections / cross-references

• For detailed coverage of antiarrhythmic drug mechanisms and side effects, review the material covered in [Episode 54].
• The concept of rate control vs. rhythm control is a core topic discussed in general cardiology management guidelines (e.g., ACC/AHA).

High-yield association table

Key terms glossary

Study optimization

Question pattern recognition

• Mechanism of Action/Drug Class: Identifying the specific ion channel or pump targeted by a drug (e.g., \text{Na}^+/\text{K}^+-AT Pase inhibition).
• Electrophysiology Correlation: Linking changes in APD to measurable EKG intervals (QRS vs QT).
• Contraindication/Safety: Recognizing absolute contraindications based on underlying cardiac conduction abnormalities (e.g., WPW syndrome).

Test yourself

Common mistakes to avoid

Common traps